{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:13:11Z","timestamp":1783476791687,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02645-x","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T04:47:23Z","timestamp":1753418843000},"page":"2369-2379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of hypoprolactinemia on cardiometabolic effects of metformin in young women: a pilot prospective cohort study"],"prefix":"10.1007","volume":"48","author":[{"given":"Robert","family":"Krysiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Kowalcze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspare","family":"Cucinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Zaami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2645_CR1","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11154-024-09921-w","volume":"25","author":"F Kelestimur","year":"2024","unstructured":"Kelestimur F, Ioachimescu AG (2024) Hypoprolactinemia, a neglected endocrine disorder. Rev Endocr Metab Disord 25:941\u2013942. https:\/\/doi.org\/10.1007\/s11154-024-09921-w","journal-title":"Rev Endocr Metab Disord"},{"key":"2645_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s11154-023-09847-9","volume":"25","author":"Z Karaca","year":"2024","unstructured":"Karaca Z, Unluhizarci K, Kelestimur F (2024) Hypoprolactinemia. Does it matter? Redefining the hypopituitarism and return from a mumpsimus: absence of proof is not the proof of absence. Rev Endocr Metab Disord 25:943\u2013951. https:\/\/doi.org\/10.1007\/s11154-023-09847-9","journal-title":"Rev Endocr Metab Disord"},{"key":"2645_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","volume":"15","author":"V Bernard","year":"2019","unstructured":"Bernard V, Young J, Binart N (2019) Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol 15:356\u2013365. https:\/\/doi.org\/10.1038\/s41574-019-0194-6","journal-title":"Nat Rev Endocrinol"},{"key":"2645_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.endien.2021.03.004","volume":"69","author":"R Krysiak","year":"2022","unstructured":"Krysiak R, Kowalcze K, Okopie\u0144 B (2022) Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: a pilot study. Endocrinol Diabetes Nutr 69:279\u2013288. https:\/\/doi.org\/10.1016\/j.endien.2021.03.004","journal-title":"Endocrinol Diabetes Nutr"},{"key":"2645_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/cen.14283","volume":"93","author":"R Krysiak","year":"2020","unstructured":"Krysiak R, Kowalcze K, Okopie\u0144 B (2020) Sexual function and depressive symptoms in young women with hypoprolactinaemia. Clin Endocrinol 93:482\u2013488. https:\/\/doi.org\/10.1111\/cen.14283","journal-title":"Clin Endocrinol"},{"key":"2645_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s11154-024-09892-y","volume":"25","author":"V Munro","year":"2024","unstructured":"Munro V, Wilkinson M, Imran SA (2024) Neuropsychological complications of hypoprolactinemia. Rev Endocr Metab Disord 25:1121\u20131126. https:\/\/doi.org\/10.1007\/s11154-024-09892-y","journal-title":"Rev Endocr Metab Disord"},{"key":"2645_CR7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s11154-024-09895-9","volume":"25","author":"G Corona","year":"2024","unstructured":"Corona G, Rastrelli G, Sparano C, Vignozzi L, Maggi M (2024) Acquired hypoprolactinemia in men, possible phenotype. Rev Endocr Metab Disord 25:1109\u20131119. https:\/\/doi.org\/10.1007\/s11154-024-09895-9","journal-title":"Rev Endocr Metab Disord"},{"key":"2645_CR8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s11154-024-09890-0","volume":"25","author":"TS Han","year":"2024","unstructured":"Han TS, Antonio L, Bartfai G, O\u2019Neill TW, Puna M, Rastrelli G, Maggi M, S\u0142owikowska-Hilczer J, Tournoy J, Vanderschueren D et al (2024) Evidence-based definition of hypoprolactinemia in European men aged 40\u201386 years: the European male ageing study. Rev Endocr Metab Disord 25:1097\u20131107. https:\/\/doi.org\/10.1007\/s11154-024-09890-0","journal-title":"Rev Endocr Metab Disord"},{"key":"2645_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11154-024-09886-w","volume":"25","author":"G Ken-Dror","year":"2024","unstructured":"Ken-Dror G, Fluck D, Lean ME, Casanueva FF, Han TS (2024) The relationship between low prolactin and type 2 diabetes. Rev Endocr Metab Disord 25:1087\u20131095. https:\/\/doi.org\/10.1007\/s11154-024-09886-w","journal-title":"Rev Endocr Metab Disord"},{"key":"2645_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","volume":"6","author":"G Corona","year":"2009","unstructured":"Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, Boddi V, Bandini E, Balercia G, Forti G (2009) Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 6:1457\u20131466. https:\/\/doi.org\/10.1111\/j.1743-6109.2008.01206.x","journal-title":"J Sex Med"},{"key":"2645_CR11","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s40618-023-02101-8","volume":"46","author":"E Maseroli","year":"2023","unstructured":"Maseroli E, Verde N, Cipriani S, Rastrelli G, Alfaroli C, Ravelli SA, Costeniero D, Scairati R, Minnetti M, Petraglia F (2023) Low prolactin level identifies hypoactive sexual desire disorder women with a reduced Inhibition profile. J Endocrinol Invest 46:2481\u20132492. https:\/\/doi.org\/10.1007\/s40618-023-02101-8","journal-title":"J Endocrinol Invest"},{"key":"2645_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12020-019-02170-x","volume":"67","author":"AJ Ponce","year":"2020","unstructured":"Ponce AJ, Galv\u00e1n-Salas T, Lerma-Alvarado RM, Ruiz-Herrera X, Hern\u00e1ndez-Cort\u00e9s T, Valencia-Jim\u00e9nez R, C\u00e1rdenas-Rodr\u00edguez LE, Mart\u00ednez de la Escalera G, Clapp C, Macotela Y (2020) Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans. Endocrine 67:331\u2013343. https:\/\/doi.org\/10.1007\/s12020-019-02170-x","journal-title":"Endocrine"},{"key":"2645_CR13","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jhep.2018.01.035","volume":"68","author":"P Zhang","year":"2018","unstructured":"Zhang P, Ge Z, Wang H, Feng W, Sun X, Chu X, Jiang C, Wang Y, Zhu D, Bi Y (2018) Prolactin improves hepatic steatosis via CD36 pathway. J Hepatol 68:1247\u20131255. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.035","journal-title":"J Hepatol"},{"key":"2645_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1210\/en.2016-1444","volume":"158","author":"X Ruiz-Herrera","year":"2017","unstructured":"Ruiz-Herrera X, de Los R\u00edos EA, D\u00edaz JM, Lerma-Alvarado RM, Mart\u00ednez de la Escalera L, L\u00f3pez-Barrera F, Lemini M, Arnold E, de la Mart\u00ednez G, Clapp C et al (2017) Prolactin promotes adipose tissue fitness and insulin sensitivity in obese males. Endocrinology 158:56\u201368. https:\/\/doi.org\/10.1210\/en.2016-1444","journal-title":"Endocrinology"},{"key":"2645_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12020-022-03145-1","volume":"78","author":"R Krysiak","year":"2022","unstructured":"Krysiak R, Kowalcze K, Okopie\u0144 B (2022) Cardiometabolic profile of young women with hypoprolactinemia. Endocrine 78:135\u2013141. https:\/\/doi.org\/10.1007\/s12020-022-03145-1","journal-title":"Endocrine"},{"key":"2645_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/biom14101335","volume":"14","author":"R Krysiak","year":"2024","unstructured":"Krysiak R, Kowalcze K, Szkr\u00f3bka W, Okopie\u0144 B (2024) Increased cardiometabolic risk in men with hypoprolactinemia: a pilot study. Biomolecules 14:1335. https:\/\/doi.org\/10.3390\/biom14101335","journal-title":"Biomolecules"},{"key":"2645_CR17","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854\u2013865","journal-title":"Lancet"},{"key":"2645_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or Metformin. N Engl J Med 346:393\u2013403. https:\/\/doi.org\/10.1056\/NEJMoa012512","journal-title":"N Engl J Med"},{"key":"2645_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000527333","volume":"147","author":"R Krysiak","year":"2022","unstructured":"Krysiak R, Kowalcze K, Okopie\u0144 B (2022) Cabergoline-induced hypoprolactinemia May attenuate cardiometabolic effects of atorvastatin: a pilot study. Cardiology 147:497\u2013506. https:\/\/doi.org\/10.1159\/000527333","journal-title":"Cardiology"},{"key":"2645_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.psychres.2016.01.031","volume":"237","author":"QJ Bo","year":"2016","unstructured":"Bo QJ, Wang ZM, Li XB, Ma X, Wang CY, de Leon J (2016) Adjunctive Metformin for antipsychotic-induced hyperprolactinemia: a systematic review. Psychiatry Res 237:257\u2013263. https:\/\/doi.org\/10.1016\/j.psychres.2016.01.031","journal-title":"Psychiatry Res"},{"key":"2645_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s12020-014-0428-2","volume":"49","author":"R Krysiak","year":"2015","unstructured":"Krysiak R, Okrzesik J, Okopie\u0144 B (2015) The effect of short-term Metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine 49:242\u2013249. https:\/\/doi.org\/10.1007\/s12020-014-0428-2","journal-title":"Endocrine"},{"issue":"Suppl 10","key":"2645_CR22","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) Diagnosis and classification of diabetes: standards of care in diabetes \u2013\u20092024. Diabetes Care 47(Suppl 10):S20\u2013S42. https:\/\/doi.org\/10.2337\/dc24-S002","journal-title":"Diabetes Care"},{"key":"2645_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/B978-0-444-59602-4.00013-7","volume":"124","author":"JA Romijn","year":"2024","unstructured":"Romijn JA (2024) Hyperprolactinemia and prolactinoma. Handb Clin Neurol 124:185\u2013195. https:\/\/doi.org\/10.1016\/B978-0-444-59602-4.00013-7","journal-title":"Handb Clin Neurol"},{"key":"2645_CR24","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/S0140-6736(16)30053-8","volume":"388","author":"CE Higham","year":"2016","unstructured":"Higham CE, Johannsson G, Shalet SM (2016) Hypopituitarism Lancet 388:2403\u20132415. https:\/\/doi.org\/10.1016\/S0140-6736(16)30053-8","journal-title":"Hypopituitarism Lancet"},{"key":"2645_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s0140-6736(00)04006-x","volume":"357","author":"JW Tomlinson","year":"2001","unstructured":"Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM (2001) Association between premature mortality and hypopituitarism. West Midlands prospective hypopituitary study group. Lancet 357:425\u2013431. https:\/\/doi.org\/10.1016\/s0140-6736(00)04006-x","journal-title":"Lancet"},{"key":"2645_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/cen.12204","volume":"79","author":"A Ciresi","year":"2013","unstructured":"Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of Cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol 79:845\u2013852. https:\/\/doi.org\/10.1111\/cen.12204","journal-title":"Clin Endocrinol"},{"key":"2645_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000357810","volume":"98","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C, Ferreri L, Pivonello C, CariatI F, Coppola G et al (2013) Effect of Cabergoline on metabolism in prolactinomas. Neuroendocrinology 98:299\u2013310. https:\/\/doi.org\/10.1159\/000357810","journal-title":"Neuroendocrinology"},{"key":"2645_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000357810","volume":"13","author":"RS Auriemma","year":"2018","unstructured":"Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A (2018) The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab 13:99\u2013106. https:\/\/doi.org\/10.1159\/000357810","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2645_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12020-012-9857-y","volume":"44","author":"SS Inancli","year":"2013","unstructured":"Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R, Cakir B (2013) Effect of Cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 44:193\u2013199. https:\/\/doi.org\/10.1007\/s12020-012-9857-y","journal-title":"Endocrine"},{"key":"2645_CR30","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s40618-020-01445-9","volume":"44","author":"R Cannarella","year":"2021","unstructured":"Cannarella R, Condorell RA, Barbagallo F, Aversa A, Calogero AE, La Vignera S (2021) TSH Lowering effects of metformin: a possible mechanism of action. J Endocrinol Invest 44:1547\u20131550. https:\/\/doi.org\/10.1007\/s40618-020-01445-9","journal-title":"J Endocrinol Invest"},{"key":"2645_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/jcph.6144","volume":"65","author":"R Krysiak","year":"2025","unstructured":"Krysiak R, Kowalcze K, Okopie\u0144 B (2025) Subclinical hyperthyroidism enhances gonadotropin-lowering effects of Metformin in postmenopausal women. J Clin Pharmacol 65:318\u2013327. https:\/\/doi.org\/10.1002\/jcph.6144","journal-title":"J Clin Pharmacol"},{"key":"2645_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"R Holman","year":"2008","unstructured":"Holman R, Paul S, Bethel M, Matthews D, Neil H (2008) 10-year follow\u2010up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577\u20131589. https:\/\/doi.org\/10.1056\/NEJMoa0806470","journal-title":"N Engl J Med"},{"key":"2645_CR33","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s11154-024-09916-7","volume":"25","author":"J Krogh","year":"2024","unstructured":"Krogh J (2024) The homeo-FIT-prolactin hypothesis: the role of prolactin in metabolic homeostasis - association or causality? Rev Endocr Metab Disord 25:1077\u20131086. https:\/\/doi.org\/10.1007\/s11154-024-09916-7","journal-title":"Rev Endocr Metab Disord"},{"key":"2645_CR34","doi-asserted-by":"publisher","first-page":"1015520","DOI":"10.3389\/fendo.2022.1015520","volume":"13","author":"R Pirchio","year":"2022","unstructured":"Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS (2022) Metabolic effects of prolactin. Front Endocrinol 13:1015520. https:\/\/doi.org\/10.3389\/fendo.2022.1015520","journal-title":"Front Endocrinol"},{"key":"2645_CR35","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/EJE-11-0447","volume":"165","author":"G Corona","year":"2011","unstructured":"Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165:687\u2013701. https:\/\/doi.org\/10.1530\/EJE-11-0447","journal-title":"Eur J Endocrinol"},{"key":"2645_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1743-6109.2010.01991.x","volume":"8","author":"G Corona","year":"2011","unstructured":"Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M (2011) Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8:272\u2013283. https:\/\/doi.org\/10.1111\/j.1743-6109.2010.01991.x","journal-title":"J Sex Med"},{"key":"2645_CR37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/13685538.2018.1557139","volume":"23","author":"J Zhang","year":"2020","unstructured":"Zhang J, Li X, Cai Z, Li H, Yang B (2020) Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male 23:607\u2013618. https:\/\/doi.org\/10.1080\/13685538.2018.1557139","journal-title":"Aging Male"},{"key":"2645_CR38","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/EJE-06-0702","volume":"156","author":"E Debing","year":"2007","unstructured":"Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den Brande P (2007) Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur J Endocrinol 156:687\u2013693. https:\/\/doi.org\/10.1530\/EJE-06-0702","journal-title":"Eur J Endocrinol"},{"key":"2645_CR39","doi-asserted-by":"publisher","first-page":"5150684","DOI":"10.1155\/2020\/5150684","volume":"2020","author":"Y Guan","year":"2020","unstructured":"Guan Y, Wang D, Bu H, Zhao T, Wang H (2020) The effect of Metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials. Int J Endocrinol 2020:5150684. https:\/\/doi.org\/10.1155\/2020\/5150684","journal-title":"Int J Endocrinol"},{"key":"2645_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1471-2407-11-56","volume":"11","author":"K Linher-Melville","year":"2011","unstructured":"Linher-Melville K, Zantinge S, Sanli T, Gerstein H, Tsakiridis T, Singh G (2011) Establishing a relationship between prolactin and altered fatty acid beta-oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer 11:56. https:\/\/doi.org\/10.1186\/1471-2407-11-56","journal-title":"BMC Cancer"},{"key":"2645_CR41","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.3390\/ijms21144987","volume":"21","author":"S Wu","year":"2020","unstructured":"Wu S, Zou MH (2020) AMPK, mitochondrial function, and cardiovascular disease. Int J Mol Sci 21:4987. https:\/\/doi.org\/10.3390\/ijms21144987","journal-title":"Int J Mol Sci"},{"key":"2645_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1530\/JME-16-0257","volume":"61","author":"TR Nardelli","year":"2018","unstructured":"Nardelli TR, Vanzela EC, Benedicto KC, Brozzi F, Fujita A, Cardozo AK, Eizirik DL, Boschero AC, Ortis F (2018) Prolactin protects against cytokine-induced beta-cell death by NFkappaB and JNK Inhibition. J Mol Endocrinol 61:25\u201336. https:\/\/doi.org\/10.1530\/JME-16-0257","journal-title":"J Mol Endocrinol"},{"key":"2645_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11033-022-07954-5","volume":"50","author":"YY Feng","year":"2023","unstructured":"Feng YY, Wang Z, Pang H (2023) Role of Metformin in inflammation. Mol Biol Rep 50:789\u2013798. https:\/\/doi.org\/10.1007\/s11033-022-07954-5","journal-title":"Mol Biol Rep"},{"key":"2645_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1515\/revneuro-2020-0082","volume":"32","author":"E Ramos-Martinez","year":"2021","unstructured":"Ramos-Martinez E, Ramos-Mart\u00ednez I, Molina-Salinas G, Zepeda-Ruiz WA, Cerbon M (2021) The role of prolactin in central nervous system inflammation. Rev NeuroscI 32:323\u2013340. https:\/\/doi.org\/10.1515\/revneuro-2020-0082","journal-title":"Rev NeuroscI"},{"key":"2645_CR45","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/oxfordjournals.humrep.a136149","volume":"10","author":"C Ferrari","year":"1995","unstructured":"Ferrari C, Piscitelli G, Crosignani PG (1995) Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum Reprod 10:1647\u20131652. https:\/\/doi.org\/10.1093\/oxfordjournals.humrep.a136149","journal-title":"Hum Reprod"},{"key":"2645_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ecl.2014.10.007","volume":"44","author":"RS Auriemma","year":"2015","unstructured":"Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A (2015) Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am 44:89\u201397. https:\/\/doi.org\/10.1016\/j.ecl.2014.10.007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2645_CR47","doi-asserted-by":"publisher","first-page":"f457","DOI":"10.1136\/bmj.f457","volume":"346","author":"O Ciani","year":"2013","unstructured":"Ciani O, Buyse M, Garside R, Pavey T, Stein K, Sterne JA, Taylor RS (2013) Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. BMJ 346:f457. https:\/\/doi.org\/10.1136\/bmj.f457","journal-title":"BMJ"},{"key":"2645_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jclinepi.2023.06.013","volume":"160","author":"AM Manyara","year":"2023","unstructured":"Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Wells V, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW et al (2023) Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review. J Clin Epidemiol 160:83\u201399. https:\/\/doi.org\/10.1016\/j.jclinepi.2023.06.013","journal-title":"J Clin Epidemiol"},{"key":"2645_CR49","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1097\/PRS.0b013e3181f44abc","volume":"126","author":"JW Song","year":"2010","unstructured":"Song JW, Chung KC (2010) Observational studies: cohort and case-control studies. Plast Reconstr Surg 126:2234\u20132242. https:\/\/doi.org\/10.1097\/PRS.0b013e3181f44abc","journal-title":"Plast Reconstr Surg"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02645-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:42:53Z","timestamp":1760362973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02645-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["2645"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02645-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No competing financial interests exist. The authors report no financial, personal, political, intellectual or religious conflicts of interest. The authors alone are responsible for the content and writing of the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Bioethical Committee of the Medical University of Silesia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional approval"}},{"value":"Authors declare have nothing to disclosure.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The participants provided written informed consent after risks and benefits of the study had been explained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}